Lymphoblastic Leukemia in Children Clinical Trial
Official title:
Association Between Mitochondrial DNA Content and Risk of Acute Leukemia in Young Adult
Verified date | July 2020 |
Source | Fourth Military Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Compelling epidemiological evidence indicates that alterations of mitochondrial DNA, including mutations and abnormal content of mitochondrial DNA (mtDNA), are associated with the initiation and development of acute lymphoblastic leukemia (ALL).The aim of this study was to explore association between mtDNA content in peripheral blood cells could be used as a risk predictor for ALL.
Status | Completed |
Enrollment | 300 |
Est. completion date | October 1, 2019 |
Est. primary completion date | October 1, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A to 16 Years |
Eligibility |
Inclusion Criteria: - 1.histological confirmed chronic lymphocytic leukemia; 2.preparing for chemotherapy; 3.no preoperative anticancer treatment. Exclusion Criteria: - 1.history of other malignancy; 2.blood transfusion within one month or prior bone marrow transplantation; 3.patients who reluctant to sign informed consent. |
Country | Name | City | State |
---|---|---|---|
China | Xiao-Fan Zhu | Tianjin | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Fourth Military Medical University | Chinese Academy of Medical Sciences |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Relative copy number of mitochondrial DNA | The ratio of mitochondrial DNA contents to hemoglobin contents was calculated for each sample from standard curves. After that, the ratio for each sample was normalized to a calibrator DNA in order to standardize between different runs, and then defined as the measurement of relative mtDNA contents.Relative expression of mtDNA were measured in young adults suffered from chronic lymphocytic leukemiawhen compared with control group. | From date of admission until the date of discharging from hospital, assessed up to 5 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05043571 -
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
|
Phase 1 | |
Recruiting |
NCT06099366 -
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children
|
Phase 2 | |
Recruiting |
NCT05648019 -
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
|
Phase 2 | |
Recruiting |
NCT05429905 -
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT05038696 -
ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.
|
Phase 1 |